Cannabidiol Pharmacotherapy for Adults With Cannabis Use Disorder
Public ClinicalTrials.gov record NCT03102918. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Investigators aim to determine Epidiolex's promise as a pharmacotherapy for cannabis use disorder. Investigators hypothesize that Epidiolex, when added to medical management, will result in greater reductions in marijuana use compared to placebo as measured by the 2 primary outcome measures: 1) quantitative THC levels and 2) self-report by Timeline Follow Back. Secondary outcome measures will include treatment retention, patient satisfaction, cannabis withdrawal, cannabis craving, depressive symptoms, anxiety symptoms, , compliance, and cigarette use.
Study identification
- NCT ID
- NCT03102918
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 10 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 19, 2016
- Primary completion
- Aug 29, 2017
- Completion
- Aug 29, 2017
- Last update posted
- Jan 24, 2019
2016 – 2017
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| McLean Hospital | Belmont | Massachusetts | 02478 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Cannabis Use Disorder trials
Other public records listing Cannabis Use Disorder. Sorted by last update posted; newest first. Not a recommendation.
- NCT07787572: Applying Neuromodulation to Boost the Efficacy of Motivational Interviewing Not yet recruiting
- NCT07685964: Pregnenolone for Cannabis Use Disorder and Depression Not yet recruiting
- NCT05453513: The Neural Underpinnings of Depression and Cannabis Use in Young People Living With HIV Recruiting
- NCT06107062: Longitudinal Outpatient Treatment for Cannabis Use Disorder Recruiting
- NCT07634835: Transcranial Magnetic Stimulation for Adolescents and Young Adults With Cannabis Use Disorder Not yet recruiting
- NCT06878859: Preliminary Efficacy Trial of a Digital Intervention for Depression and Cannabis Use Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03102918, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 24, 2019 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03102918 live on ClinicalTrials.gov.